ArticleJournal of neuro-oncology2026
Frameless gamma knife stereotactic radiosurgery for over two hundred vestibular schwannoma patients - a single institution experience.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGamma Knife radiosurgery (GKRS) as definitive treatment for vestibular schwannomas (VS) provides high rates of tumor control. Traditionally, treatment immobilization necessitated a rigid stereotactic frame. The Gamma Knife Icon (Elekta AB) system enables frameless, mask-based immobilization. This study evaluates tumor control and hearing preservation after single- or five-fraction frameless GKRS for VS.
methodsWe reviewed 206 patients with unilateral VS who underwent definitive single- or five-fraction GKRS with frameless immobilization between 2017 and 2024, ultimately including 170 patients with untreated VS. Radiographic follow-up was available for 112 patients, 40 of whom had both baseline and follow-up audiometric follow-up. Tumor control was assessed volumetrically on MRI and categorized as progressive, stable, partial response, complete response, or transient swelling. Serviceable hearing was defined as American Academy of Otolaryngology-Head and Neck Surgery class A or B. Kaplan-Meier methods estimated tumor control and and serviceable hearing preservation, and Cox regression evaluated associations with outcomes.
resultsAmong 112 patients with radiographic follow-up (median 2.3 years), 1- and 3-year tumor control rates were 97.1% and 93.7%. At last follow-up, 75.9% demonstrated stable disease or partial response, and 7 patients (6.3%) developed progressive disease. Of 76 patients with baseline serviceable hearing, 40 had audiometric follow-up; serviceable hearing preservation at 1 and 3 years was 71.1% and 33.8%, though 3-year data was limited. No factors were significantly associated with tumor control or hearing preservation.
conclusionsFrameless GKRS for VS achieves acceptable tumor control that is comparable to historical frame-based series. These findings support the selective use of frameless GKRS, although warrant prospective studies with standardized radiologic and audiologic follow-up.
Indexed as
Identifiers
42521876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.